EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, NVN Liquidation's enterprise value is $-8.67 Mil.
NVN Liquidation's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 was $24.71 Mil. Therefore, NVN Liquidation's EV-to-Revenue for today is -0.35.
The historical rank and industry rank for NVN Liquidation's EV-to-Revenue or its related term are showing as below:
NOVNQ's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.63 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-04-26), NVN Liquidation's stock price is $0.0008.
NVN Liquidation's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $1.05. Therefore, NVN Liquidation's PS Ratio for today is 0.00.
NVN Liquidation EV-to-Revenue Historical Data
The historical data trend for NVN Liquidation's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NVN Liquidation's EV-to-Revenue
For the Biotechnology subindustry, NVN Liquidation's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NVN Liquidation's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NVN Liquidation's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where NVN Liquidation's EV-to-Revenue falls into.
NVN Liquidation's current Enterprise Value is $-8.67 Mil.
NVN Liquidation's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NVN Liquidation's share price for today is $0.0008.
NVN Liquidation's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NVN Liquidation EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of NVN Liquidation's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
NVN Liquidation (NVN Liquidation) Business Description
NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NOVNQ has been successfully added to your 